Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC) Allergan Aesthetics (ABBV) will present 21 evidence-based e-posters at AMWC Monaco, March 26-28, 2026, covering clinical, real-world and preclinical research. Key highlights include investigational neurotoxin trenibotulinumtoxinE with rapid improvement as early as 8 hours and short 2-3 week duration, BOTOX Cosmetic real-world satisfaction and multimodal care trends, VYC-12L/VYC-20L hyaluronic acid data with up to 6 months of benefit, HA-CaHA durability to 18 months, and CoolSculpting molecular evidence for lasting fat reduction.

#ABBV Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)

www.stocktitan.net/news/ABBV/allergan-aesth...

Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco Allergan Aesthetics (NYSE:ABBV) introduced the concept of an "Undetectable† Era" for hyaluronic acid (HA) injectables at AMWC Monaco on March 26, 2026. Research of 12,000 consumers in nine countries found strong demand for subtle, natural-looking results and personalized treatment plans.JUVÉDERM® is presented as a versatile HA portfolio supporting individualized, long-lasting, reversible outcomes and practitioner-led multimodal approaches such as AA Signature™ and MD Codes™ training.

#ABBV Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

www.stocktitan.net/news/ABBV/allergan-aesth...

What's Going On With AbbVie Stock Today? - AbbVie (NYSE:ABBV) Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis.

What's Going On With AbbVie Stock Today? Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress...

#ABBV #ABBV #News #why #it's #moving #Movers #ABBV #ABBV #News #Movers

Origin | Interest | Match

#ABBV #WMT #ED #8d0e648c-71e8-4ee5-92b6-328738bea76c #investing #Health #Care

Origin | Interest | Match

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults AbbVie (NYSE: ABBV) announced positive topline Phase 1 multiple ascending dose results for ABBV-295 on March 9, 2026. ABBV-295, a long-acting amylin analog, produced dose-dependent mean weight reductions of -7.75% to -9.79% at week 12 (weekly dosing) and -7.86% to -9.73% at week 13 (alternate dosing), versus placebo ~-0.25%.The study tested 2–14 mg doses, enrolled mostly male participants (88.3%), showed a favorable tolerability profile with no serious adverse events, and reported mostly mild gastrointestinal events early in treatment. Full data will be presented at a future scientific conference.

#ABBV AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

www.stocktitan.net/news/ABBV/abb-vie-announ...

ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS Allergan Aesthetics (NYSE:ABBV) released data on March 4, 2026 showing Medical Weight Loss (MWL) is reshaping aesthetic demand, with patients prioritizing facial appearance and volume restoration.Key metrics: 67% changed goals toward appearance, 61% report midface volume loss, 81% of HCPs favor HA fillers, and 60% of GLP-1 users obtain medications from providers who also offer aesthetic services (up from 49%).

#ABBV ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

www.stocktitan.net/news/ABBV/allergan-aesth...

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 AFFIRM study of risankizumab (SKYRIZI) subcutaneous induction in adults with moderately to severely active Crohn's disease on March 2, 2026. Co-primary endpoints at week 12 met: CDAI clinical remission 55% vs 30% and endoscopic response 44% vs 14% versus placebo (both p<0.0001). Among 12-week responders who continued maintenance, 67% achieved clinical remission and 57% achieved endoscopic response at week 24. Safety was consistent with known profile; most common adverse events were upper respiratory tract infection, abdominal pain and arthralgia.

#ABBV AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

www.stocktitan.net/news/ABBV/abb-vie-announ...

#LLY #ISRG #ABBV #d91d24b9-06ae-4809-beb0-160e4145f84f #investing #Health #Care

Origin | Interest | Match

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GD 243.2x
2. #ABBV 150.9x
3. #CTRA 82.7x
4. #WSM 56.4x
5. #FLUT 35.6x

#OptionFlow #OptionsTrading #Trading

#ABBV on my watchlist

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ABBV, #CTRA, #WSM, #FLUT, #EXE

#OptionFlow #OptionsTrading #Trading

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.

#WST #ABBV West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

www.stocktitan.net/news/WST/west-signs-agre...

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.

#WST #ABBV AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

www.stocktitan.net/news/WST/abb-vie-to-acqu...

📢 Stocks Trending NOW: #APLD #LMT #INTC #BX #ABBV #RTX #RVMD #NOC #LUCY #STZ

📢 Stocks Trending NOW: #AMCI #PG #JNJ #ABBV

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of difficult-to-treat blood cancers. NORTH CHICAGO, Ill., Dec. 2, 2025/ PRNewswire/-- AbbVie today announced it will unveil new data at the 2025 American Society of...

#ABBV AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

www.stocktitan.net/news/ABBV/abb-vie-to-fea...

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma AbbVie (NYSE: ABBV) announced U.S. FDA approval of EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma after ≥1 prior systemic therapy.The approval follows Phase 3 EPCORE FL-1 where EPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21), achieved 89% ORR and 74% complete response, and median PFS was not reached versus 11.2 months for R2. Safety was consistent with known profiles; CRS occurred in 24% (mostly Grade 1–2).

#ABBV AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

www.stocktitan.net/news/ABBV/abb-vie-announ...

#ABBV AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

www.stocktitan.net/news/ABBV/abb-vie-announ...

📢 Stocks Trending NOW: #AMZN #NFLX #ABBV #XOM #AAPL #CVX #RDDT #GETY #CTM #INTS

AbbVie Reports Third-Quarter 2025 Financial Results Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis...

#ABBV AbbVie Reports Third-Quarter 2025 Financial Results

www.stocktitan.net/news/ABBV/abb-vie-report...

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo AbbVie (NYSE: ABBV) reported positive topline results from two replicate Phase 3 studies of upadacitinib 15 mg once daily in adults and adolescents with non-segmental vitiligo, announcing that both studies met co-primary endpoints at week 48 for T-VASI 50 (≥50% total-body repigmentation) and F-VASI 75 (≥75% facial repigmentation).Key efficacy: T-VASI 50 rates were 19.4% and 21.5% on drug versus 5.9% placebo; F-VASI 75 rates were 25.2% and 23.4% on drug versus 5.9% and 6.9% placebo; F-VASI 50 was 48.1% and 43.4% versus 12.7% and 12.9% placebo. Safety was consistent with known profiles: common TEAEs included upper respiratory infection, acne and nasopharyngitis; no new safety signals, no adjudicated MACE or VTE.Use in non-segmental vitiligo is not approved and has not been evaluated by regulators.

#ABBV AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

www.stocktitan.net/news/ABBV/abb-vie-announ...

PSL reveals W14 Regional 3 S5 Results! stock of the week: Caterpillar

#PNW def #ABT by 3.493 pts
#CNP def #NTRS by 0.918 pts
#BRK.B def #CCI by 0.905 pts
#VTR def #AJG by 11.117 pts
#CRWD def #TRV by 0.884 pts
#GWW def #MDT by 0.493 pts
#CAT def #GRMN
#ITW def #ABBV

#stockmarket #investing #stocks

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ABBV 19.4x
2. #ERO 9.4x
3. #MCHP 6.8x
4. #FLNC 6.6x
5. #WMT 4.6x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ABBV, #ERO, #MCHP, #FLNC, #TTI

#OptionFlow #OptionsTrading #Trading

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease AbbVie (NYSE: ABBV) announced that on October 13, 2025 the U.S. FDA approved a supplemental NDA updating the indication for RINVOQ (upadacitinib) to treat adults with moderately to severely active ulcerative colitis and Crohn's disease.The updated label permits RINVOQ to be used prior to tumor necrosis factor (TNF) blockers for patients for whom TNF blockers are clinically inadvisable and allows use after the patient has received at least one approved systemic therapy. The change expands prescribing options for physicians treating inflammatory bowel disease.The release reiterates RINVOQ safety considerations, including risks of serious infections, increased risk of death and major cardiovascular events in people age 50+ with ≥1 heart disease risk factor, certain cancers, blood clots, serious allergic reactions, and gastrointestinal tears.

#ABBV U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

www.stocktitan.net/news/ABBV/u-s-food-and-d...

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer By the makers of BOTOX ® Cosmetic, SkinMedica ®' s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA 5 ® moisturizer is designed to support the skin barrier and microbiome for bouncy, dewy, and soft skin.. IRVINE, Calif., Oct. 9, 2025/ PRNewswire/-- Allergan Aesthetics, an AbbVie company, today announced the rollout...

#ABBV SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

www.stocktitan.net/news/ABBV/skin-medica-de...

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor AbbVie (NYSE: ABBV) reported positive topline results from the Phase 2 ELATE trial of onabotulinumtoxinA (BOTOX) for upper limb essential tremor on Oct 6, 2025. The study met its primary endpoint at week 18: TREDS-R total unilateral score change was -2.61 for onabotulinumtoxinA vs -1.61 for placebo (p=0.029). The trial also met all six secondary endpoints. Safety was consistent with the known profile of onabotulinumtoxinA; the most common adverse event was localized, mostly mild-to-moderate muscular weakness (24.5% on active vs 2.3% placebo). Results will be presented at the International Congress of Parkinson's Disease and Movement Disorders on Oct 8, 2025. BOTOX for essential tremor is not approved by the FDA or other regulators.

#ABBV AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

www.stocktitan.net/news/ABBV/abb-vie-announ...

PSL reveals W12 Regional 3 S5 Results! stock of the week: Caterpillar

#PNW def #CCI by 3.423 pts
#VTR def #CNP by 0.931 pts
#TRV def #ABT by 1.946 pts
#GWW def #NTRS by 0.351 pts
#GRMN def #BRK.B by 6.875 pts
#AJG def #ITW by 2.532 pts
#ABBV def #CRWD by 3.314
#CAT def #MDT

#stockmarket #investing